Discovering Novel & Innovative Cancer Drugs
Cleave Biosciences is a biopharmaceutical company pioneering the development of novel protein homeostasis inhibitors for the treatment of cancer. Cleave’s lead drug development candidate is CB-5083 a potent, oral, selective, first-in-class inhibitor of p97. p97 is a critical AAA (ATPases Associated with diverse cellular Activities) ATPase that controls various aspects of protein homeostasis.
Our discovery programs aim to build upon our success at targeting p97 by discovering and developing inhibitors against other AAA ATPases that play important roles in cancer. Members of this enzyme class have critical roles in controlling various pathways that are critical for the growth and continued viability of cancer cells.
Cleave’s drug discovery team has revealed the molecular features that define several cancers that are dependent on p97 for their growth and survival. Our early stage programs targeting novel AAA ATPases will use similar approaches to enable a precision medicine approach in early clinical trials for people with difficult to treat solid tumors and hematologic malignancies.